Key Takeaways From Arcus Biosciences Analyst Ratings

Arcus Biosciences +2.74%

Arcus Biosciences

RCUS

17.24

+2.74%

Arcus Biosciences (NYSE:RCUS) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 4 0 0 0
Last 30D 1 1 0 0 0
1M Ago 0 1 0 0 0
2M Ago 0 0 0 0 0
3M Ago 0 2 0 0 0

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $35.8, a high estimate of $42.00, and a low estimate of $30.00. A 16.26% drop is evident in the current average compared to the previous average price target of $42.75.

price target chart

Interpreting Analyst Ratings: A Closer Look

A clear picture of Arcus Biosciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Robert Driscoll Wedbush Lowers Outperform $30.00 $36.00
Mara Goldstein Mizuho Lowers Buy $42.00 $51.00
Robert Driscoll Wedbush Maintains Outperform $36.00 -
Terence Flynn Morgan Stanley Lowers Overweight $35.00 $38.00
Li Watsek Cantor Fitzgerald Lowers Overweight $36.00 $46.00

Key Insights:

  • Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Arcus Biosciences. This offers insight into analysts' perspectives on the current state of the company.
  • Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Arcus Biosciences compared to the broader market.
  • Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Arcus Biosciences's stock. This examination reveals shifts in analysts' expectations over time.

For valuable insights into Arcus Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Arcus Biosciences analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Arcus Biosciences: A Closer Look

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.

Arcus Biosciences: A Financial Overview

Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.

Negative Revenue Trend: Examining Arcus Biosciences's financials over 3 months reveals challenges. As of 30 September, 2023, the company experienced a decline of approximately -3.03% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Arcus Biosciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -221.88%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Arcus Biosciences's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -13.08%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -5.89%, the company showcases effective utilization of assets.

Debt Management: With a below-average debt-to-equity ratio of 0.02, Arcus Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.

The Basics of Analyst Ratings

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via